Literature DB >> 10722966

Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography (FDG PET), MRI of the brain and biochemical observations in a patient with 4-hydroxybutyric aciduria; a progressive neurometabolic disease.

M A Al-Essa1, S M Bakheet, Z J Patay, J E Powe, P T Ozand.   

Abstract

We report a five-year-old boy with 4-hydroxybutyric aciduria. The child presented with global developmental delay, severe hypotonia and myoclonic seizures. The urine 4-hydroxybutyric acid was 1038 times that of normal, and other organic acids related to its further metabolism were also increased. Electroencephalography showed findings indicative of cerebral dysfunction. However, other neurophysiological studies were normal. Clinical improvement was observed after the administration of vigabatrin and dextromethorphan. Magnetic resonance imaging of the brain revealed cerebellar vermin atrophy and subtle white matter changes in the cerebral hemispheres. Fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomographic (FDG PET) scan of the brain showed a marked decrease in the cerebellar metabolism, probably related to atrophy of cerebellar vermis and secondary cerebellar deafferentation. FDG PET scan is found to be of value in the understanding and assessment of brain functional alterations. It may be useful in monitoring and optimizing treatment strategies of this rare disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722966     DOI: 10.1016/s0387-7604(99)00121-7

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

Review 1.  Succinic semialdehyde dehydrogenase: biochemical-molecular-clinical disease mechanisms, redox regulation, and functional significance.

Authors:  Kyung-Jin Kim; Phillip L Pearl; Kimmo Jensen; O Carter Snead; Patrizia Malaspina; Cornelis Jakobs; K Michael Gibson
Journal:  Antioxid Redox Signal       Date:  2011-04-10       Impact factor: 8.401

Review 2.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

3.  Cerebellar atrophy in human and murine succinic semialdehyde dehydrogenase deficiency.

Authors:  Maria T Acosta; Jeeva Munasinghe; Phillip L Pearl; Maneesh Gupta; Andrey Finegersh; K Michael Gibson; William H Theodore
Journal:  J Child Neurol       Date:  2010-05-05       Impact factor: 1.987

4.  Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Phillip L Pearl; Lovy Shukla; William H Theodore; Cornelis Jakobs; K Michael Gibson
Journal:  Brain Dev       Date:  2011-06-12       Impact factor: 1.961

Review 5.  Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men.

Authors:  P L Pearl; K M Gibson; M A Cortez; Y Wu; O Carter Snead; I Knerr; K Forester; J M Pettiford; C Jakobs; W H Theodore
Journal:  J Inherit Metab Dis       Date:  2009-01-28       Impact factor: 4.982

Review 6.  Neuroimaging findings in children with paediatric neurotransmitter diseases.

Authors:  Wang-Tso Lee; Wen-Chin Weng; Shinn-Forng Peng; Kai-Yuan Tzen
Journal:  J Inherit Metab Dis       Date:  2009-05-20       Impact factor: 4.982

Review 7.  Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism.

Authors:  P Malaspina; J-B Roullet; P L Pearl; G R Ainslie; K R Vogel; K M Gibson
Journal:  Neurochem Int       Date:  2016-06-14       Impact factor: 3.921

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.